Stephanie B. Hastings, Ph.D. | September 20, 2018

Matched FFPE and ctDNA Analysis using Illumina TruSightTumor 170 NGS Assay

Technical feasibility for utilizing TruSightTumor 170 NGS assay (+UMIs) to analyze ctDNA
This presentation, given at the BioPharma Innovation Conference in September 2018, highlights Q2 Solutions | EA Genomics' collaboration with Illumina and an additional pharma partner, where we have demonstrated technical feasibility for utilizing TruSight Tumor 170 Next Generation Sequencing (NGS) assay in the presence of UMIs to enable low frequency mutation detection (down to ~0.4%) in circulating-tumor DNA.

Download this presentation to learn more.

Related Services:
Q2 Solutions Genomic Laboratory Services

Genomic Know-How® for your drug development needs

Genomic Assays for Clinical Development

Identifying the right approach from a wealth of potential options

Tumor Mutational Burden (TMB) Assay for Response to Immunotherapy

TMB assay utilizing whole exome sequencing (WES) methodology and proprietary variant analysis compendium

T-cell Receptor (TCR) Sequencing Assay for Characterization of Adaptive Immune Response

Detects TCRβ and TCRγ clonotypes expressed at the mRNA level

Read More